CAMLINFINE

Camlin Fine Sciences Share Price

 

 

Start SIP in CAMLINFINE

Start SIP

Performance

  • Low
  • ₹149
  • High
  • ₹156
  • 52 Week Low
  • ₹110
  • 52 Week High
  • ₹333
  • Open Price₹156
  • Previous Close₹156
  • Volume271,849

Investment Returns

  • Over 1 Month -20.69%
  • Over 3 Month -26.33%
  • Over 6 Month -43.32%
  • Over 1 Year + 26.16%

Smart Investing Starts Here Start SIP with Camlin Fine Sciences for Steady Growth!

Invest Now

Camlin Fine Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -98.7
  • PEG Ratio
  • -1.1
  • Market Cap Cr
  • 2,884
  • P/B Ratio
  • Average True Range
  • 7.32
  • EPS
  • 1.11
  • Dividend Yield
  • 0
  • MACD Signal
  • -9.28
  • RSI
  • 32.94
  • MFI
  • 38.34

Camlin Fine Sciences Financials

Camlin Fine Sciences Technicals

EMA & SMA

Current Price
₹150.14
-5.42 (-3.48%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹164.37
  • 50 Day
  • ₹181.62
  • 100 Day
  • ₹197.01
  • 200 Day
  • ₹195.23

Resistance and Support

151.57 Pivot Speed
  • R3 160.69
  • R2 158.13
  • R1 154.13
  • S1 147.57
  • S2 145.01
  • S3 141.01

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Camlin Fine Sciences manufactures specialty chemicals, including antioxidants and aroma chemicals. The company operates facilities in India and internationally, serving industries such as food, feed, pharmaceuticals, and petrochemicals with high-quality, sustainable chemical solutions.

Camlin Fine Sciences has an operating revenue of Rs. 1,754.33 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 3% needs improvement, ROE of -15% is poor and needs improvement. The company has a reasonable debt to equity of 30%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 36 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 159 indicates it belongs to a poor industry group of Chemicals-Basic and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Camlin Fine Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-10 Quarterly Results
2025-09-29 Preferential Issue of shares
2025-08-08 Quarterly Results
2025-05-23 Audited Results
2025-02-14 Quarterly Results

Camlin Fine Sciences F&O

Camlin Fine Sciences Shareholding Pattern

48.03%
7.04%
2.14%
0%
26.89%
15.9%

About Camlin Fine Sciences

  • NSE Symbol
  • CAMLINFINE
  • BSE Symbol
  • 532834
  • Chairman & Managing Director
  • Mr. Ashish Dandekar
  • ISIN
  • INE052I01032

Similar Stocks to Camlin Fine Sciences

Camlin Fine Sciences FAQs

Camlin Fine Sciences share price is ₹150 As on 08 December, 2025 | 01:27

The Market Cap of Camlin Fine Sciences is ₹2884 Cr As on 08 December, 2025 | 01:27

The P/E ratio of Camlin Fine Sciences is -98.7 As on 08 December, 2025 | 01:27

The PB ratio of Camlin Fine Sciences is 3.2 As on 08 December, 2025 | 01:27

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23